The use of regular low-dose aspirin therapy among the patient population for effectively managing cardiovascular diseases is well established, given its role as prophylaxis in vascular diseases and colorectal cancer. However, evidence and recommendations of low-dose aspirin as an adjuvant treatment for a variety of cancer types are still emerging. The emergence of benefits is largely constrained by the lack of randomized trials to assess the effect.
A recent systematic review of several observational studies has shown light on the significance of the role of aspirin in cancer treatment. The review is made by a team of researchers at the U.K. and led by a professor at Cardiff University, Cardiff, who made meta-analyses of the 71 studies with over 120 thousand patients taking aspirin participated in them. This included 29 observational studies on patients taking aspirin after being diagnosed with colorectal cancer. The review essentially sought to assess the role of low-dose adjuvant aspirin in the overall prognosis rate in various cancer, key of them were bowel, breast, and prostate cancer.
Low-dose Aspirin Use found to boost Survival Rates in Various Cancer Patients
The reviewers found in the review that any given time, there was a rise in survival rate in patients by 20-30% than those who didn’t take the drug. The review also found that in at least 10 studies, there was evidence of the role of aspirin therapy in the reduction of metastatic spread of certain cancers. In one of the studies on colon cancer, they found that a patient on the low-dose aspirin therapy showed the same prognosis outcome than those with lower age but not taking the drug.
Overall, the systematic review found substantial evidence suggestive of the therapeutic benefits of aspirin in a range of cancers, including those that are rare. Furthermore, in several studies there was no conclusive evidence of the role of aspirin intake on the stomach bleeds in patients as a fallout of the adverse effect of taking aspirin.
Evidence of Benefits of Aspirin Therapy Limited
However, the vast evidence of the beneficial role of aspirin therapy notwithstanding, what really limits the scope is the fact almost all of these were results from reviewing observational studies rather randomized trials. The inherent biases were not given proper attention. Moreover, there was a marked lack of consistency of the results across these studies. However, as the project supervisor suggests that the relevance of the evidence should not be belittled and calls for people to take part in randomized trials.